Security
uniQure N.V. Ordinary Shares · QURE
QURENASDAQCommon stockCurrentCIK 1590560Updated Nov 7, 2026
Name history
uniQure B.V. · through Feb 6, 2014
QURE price & chart
Loading TradingView…
NASDAQ:QURE on TradingView ↗About the company
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B - an historic achievement based on more than a decade of research and clinical development - represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com
In the news
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE ↗
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm ↗
Recent filings
144 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G/A - filed by JPMORGAN CHASE & CO regarding uniQure N.V.
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
S-8 filing
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 888,382,000Source | 645,806,000Source | 871,550,000Source | 584,890,000Source | 730,846,000Source | 778,706,000Source | 605,403,000Source | 770,050,000Source | 824,908,000Source | 556,536,000Source | 831,689,000Source | 704,964,000Source |
| Property, Plant and Equipment, NetUSD | 15,402,000Source | 25,566,000Source | 45,946,000Source | 17,492,000Source | 26,186,000Source | 12,014,000Source | 18,081,000Source | 44,554,000Source | 13,800,000Source | 20,424,000Source | 46,548,000Source | 50,532,000Source |
| GoodwillUSD | 25,327,000Source | 24,084,000Source | 25,273,000Source | 25,340,000Source | 23,112,000Source | 24,811,000Source | 23,351,000Source | 25,795,000Source | 25,355,000Source | 22,414,000Source | 26,379,000Source | 25,581,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | 69,990,000Source | — | — | 72,790,000Source | 71,043,000Source | 60,481,000Source | 58,778,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 597,056,000Source | 251,626,000Source | 229,484,000Source | 253,778,000Source | 287,877,000Source | 139,994,000Source | 217,229,000Source | 243,062,000Source | 80,240,000Source | 158,930,000Source | 241,360,000Source | 228,012,000Source |
| Inventory, NetUSD | — | — | 15,654,000Source | — | — | — | — | 7,672,000Source | — | — | 12,024,000Source | 6,924,000Source |
| Assets, CurrentUSD | 716,193,000Source | 464,138,000Source | 693,626,000Source | 408,573,000Source | 591,968,000Source | 615,744,000Source | 435,421,000Source | 596,003,000Source | 655,986,000Source | 390,289,000Source | 651,853,000Source | 476,774,000Source |
| Operating Lease, Right-of-Use AssetUSD | 13,079,000Source | 14,833,000Source | 30,360,000Source | 13,635,000Source | 14,925,000Source | 12,261,000Source | 13,466,000Source | 27,695,000Source | 12,525,000Source | 13,647,000Source | 28,789,000Source | 32,726,000Source |
| Other Assets, NoncurrentUSD | 5,493,000Source | 1,453,000Source | 6,018,000Source | 5,494,000Source | 5,278,000Source | 5,542,000Source | 5,429,000Source | 5,298,000Source | 5,561,000Source | 1,399,000Source | 5,363,000Source | 6,061,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 659,636,000Source | 589,985,000Source | 602,766,000Source | 588,893,000Source | 633,739,000Source | 629,363,000Source | 571,717,000Source | 623,296,000Source | 626,007,000Source | 563,288,000Source | 624,019,000Source | 228,955,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,678,000Source | 2,932,000Source | 2,883,000Source | 3,250,000Source | 2,930,000Source | 3,728,000Source | 3,240,000Source | 2,919,000Source | 3,688,000Source | 2,945,000Source | 2,883,000Source | 2,838,000Source |
| Additional Paid in CapitalUSD | 1,575,663,000Source | 1,166,291,000Source | 1,141,662,000Source | 1,262,971,000Source | 1,162,823,000Source | 1,587,971,000Source | 1,257,853,000Source | 1,155,904,000Source | 1,582,371,000Source | 1,173,068,000Source | 1,148,749,000Source | 1,113,393,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,291,850,000Source | -1,056,704,000Source | -817,203,000Source | -1,211,321,000Source | -1,012,326,000Source | -1,382,471,000Source | -1,173,602,000Source | -956,027,000Source | -1,328,936,000Source | -1,129,965,000Source | -890,409,000Source | -581,931,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -58,745,000Source | -56,698,000Source | -58,558,000Source | -58,903,000Source | -56,320,000Source | -59,885,000Source | -53,805,000Source | -56,042,000Source | -58,222,000Source | -52,800,000Source | -53,553,000Source | -58,291,000Source |
| Stockholders' Equity Attributable to ParentUSD | 228,746,000Source | 55,821,000Source | 268,784,000Source | -4,003,000Source | 97,107,000Source | 149,343,000Source | 33,686,000Source | 146,754,000Source | 198,901,000Source | -6,752,000Source | 207,670,000Source | 476,009,000Source |
| Liabilities and EquityUSD | 888,382,000Source | 645,806,000Source | 871,550,000Source | 584,890,000Source | 730,846,000Source | 778,706,000Source | 605,403,000Source | 770,050,000Source | 824,908,000Source | 556,536,000Source | 831,689,000Source | 704,964,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 100,632,000Source | 71,273,000Source | 68,607,000Source | 40,929,000Source | 80,468,000Source | 59,197,000Source | 36,310,000Source | 63,473,000Source | 62,919,000Source | 40,053,000Source | 73,675,000Source | 75,919,000Source |
| Operating Lease, Liability, CurrentUSD | 3,914,000Source | 4,298,000Source | 7,888,000Source | 3,909,000Source | 3,625,000Source | 2,992,000Source | 3,698,000Source | 7,997,000Source | 3,862,000Source | 3,601,000Source | 8,344,000Source | 8,382,000Source |
| Accounts Payable, CurrentUSD | 6,228,000Source | 5,441,000Source | 5,584,000Source | 5,541,000Source | 4,407,000Source | 4,399,000Source | 5,268,000Source | 5,231,000Source | 5,170,000Source | 7,227,000Source | 6,586,000Source | 10,984,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,361,000Source | 12,185,000Source | 28,977,000Source | 10,946,000Source | 12,369,000Source | 10,388,000Source | 10,906,000Source | 26,983,000Source | 9,832,000Source | 11,136,000Source | 28,316,000Source | 31,719,000Source |
| Deferred Income Tax Liabilities, NetUSD | 7,958,000Source | 7,627,000Source | 4,917,000Source | 7,963,000Source | 7,323,000Source | 7,796,000Source | 7,338,000Source | 7,376,000Source | 7,967,000Source | 7,043,000Source | 7,543,000Source | 8,257,000Source |
| Other Liabilities, NoncurrentUSD | 5,544,000Source | 8,919,000Source | 1,093,000Source | 6,023,000Source | 3,054,000Source | 2,677,000Source | 6,351,000Source | 3,321,000Source | 3,655,000Source | 7,942,000Source | 3,700,000Source | 935,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 51,947,000Source | 32,301,000Source | 28,427,000Source | 31,479,000Source | 26,491,000Source | 43,201,000Source | 27,344,000Source | 22,658,000Source | 41,292,000Source | 29,225,000Source | 30,534,000Source | 30,571,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | — | — | — | — | —Source | —Source | —Source | —Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 51,880,000Source | 51,113,000Source | 101,431,000Source | 51,842,000Source | 102,507,000Source | 49,942,000Source | 51,592,000Source | 102,120,000Source | 49,699,000Source | 51,324,000Source | 101,749,000Source | 102,791,000Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | — | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -53,535,000Source | -43,637,000Source | -198,971,000Source | -239,556,000Source | -308,478,000Source | -126,789,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | — | — | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,090,000Source | 4,410,000Source | 17,679,000Source | 22,258,000Source | 35,093,000Source | 34,204,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | — | -2,421,000Source | 6,740,000Source | 6,924,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -557,000Source | -2,093,000Source | -2,667,000Source | 1,520,000Source | -4,169,000Source | 9,238,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | 1,105,000Source | -120,000Source | — | — | 500,000Source | 500,000Source | 1,588,000Source | 2,284,000Source | 1,811,000Source | -1,494,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -38,243,000Source | -44,100,000Source | -177,963,000Source | -182,728,000Source | -145,929,000Source | -145,060,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | — | 1,900,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 98,560,000Source | 20,099,000Source | -321,619,000Source | 162,968,000Source | -205,686,000Source | -182,734,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 140,000Source | 126,000Source | 439,000Source | 3,368,000Source | 7,154,000Source | 17,688,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 550,000Source | 80,670,000Source | 415,398,000Source | -59,486,000Source | 362,721,000Source | 1,445,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 53,050,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 59,735,000Source | 58,329,000Source | -78,527,000Source | -84,215,000Source | 13,371,000Source | -328,180,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 598,549,000Source | 253,079,000Source | 255,272,000Source | 291,039,000Source | 141,536,000Source | 218,658,000Source | 81,802,000Source | 160,329,000Source | 244,544,000Source | 231,173,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 6,720,000Source | 6,491,000Source | 25,069,000Source | 20,567,000Source | 16,878,000Source | 9,247,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 7,542,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -1,132,000Source | 1,660,000Source | 5,657,000Source | -4,969,000Source | 2,265,000Source | -1,831,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | 22,258,000Source | 35,093,000Source | 34,204,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 9,100,000Source | 10,100,000Source | 10,300,000Source | 8,200,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -428,000Source | 7,564,000Source | 18,638,000Source | -989,000Source | -2,294,000Source | 7,172,000Source | 26,131,000Source | -10,507,000Source | -1,691,000Source | 23,235,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -2,178,000Source | 7,105,000Source | 23,019,000Source | -15,415,000Source | 2,206,000Source | 22,083,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 1,171,000Source | — | — | — | — | — | 1,150,000Source | — | — |
| GoodwillUSD | — | — | 25,327,000Source | 24,084,000Source | 25,340,000Source | 23,112,000Source | 24,811,000Source | 23,351,000Source | 25,355,000Source | 22,414,000Source | 26,379,000Source | 25,581,000Source |
| Income Tax Expense (Benefit)USD | — | — | 8,626,000Source | -31,000Source | 425,000Source | 948,000Source | 488,000Source | 496,000Source | 5,631,000Source | 2,429,000Source | 1,921,000Source | -1,470,000Source |
| InterestExpenseNonoperatingUSD | — | — | 16,721,000Source | 16,611,000Source | 15,591,000Source | 16,157,000Source | 14,031,000Source | 15,109,000Source | 61,994,000Source | 63,741,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | 6,300,000Source | 1,600,000Source | — |
| Investment Income, InterestUSD | — | — | 3,503,000Source | 4,866,000Source | 3,524,000Source | 5,805,000Source | 5,229,000Source | 4,127,000Source | 16,967,000Source | 21,415,000Source | 19,562,000Source | 609,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -80,529,000Source | -44,378,000Source | -37,719,000Source | -56,299,000Source | -53,535,000Source | -43,637,000Source | -198,971,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -44,378,000Source | — | -56,299,000Source | — | -43,637,000Source | -198,971,000Source | -239,556,000Source | -308,478,000Source | -126,789,000Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 289,455,000Source | 252,650,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,222,000Source | — | — | — | 3,769,000Source | — | 10,905,000Source | — | — | 2,760,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | 2,549,000Source | — |
| Restructuring Costs and Asset Impairment ChargesUSD | — | — | — | — | — | — | — | — | — | — | 3,987,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 3,701,000Source | 2,287,000Source | 5,262,000Source | 11,126,000Source | — | 1,567,000Source | 16,098,000Source | 27,119,000Source | 15,843,000Source | 106,483,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of RevenueUSD | — | — | 398,000Source | 264,000Source | 656,000Source | 234,000Source | 219,000Source | 197,000Source | 1,686,000Source | 1,267,000Source | 65,000Source | 1,254,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 19,438,000Source | 11,575,000Source | 13,500,000Source | 15,767,000Source | 20,068,000Source | 10,908,000Source | 65,456,000Source | 52,657,000Source | 74,591,000Source | 55,059,000Source |
| Operating Income (Loss)USD | — | — | -51,035,000Source | -40,228,000Source | -43,865,000Source | -44,010,000Source | -45,720,000Source | -39,331,000Source | -185,349,000Source | -184,294,000Source | -282,871,000Source | -143,159,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,222,000Source | — | — | — | 3,769,000Source | — | 10,905,000Source | — | — | 2,760,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -71,903,000Source | -44,409,000Source | -37,294,000Source | -55,351,000Source | -53,047,000Source | -43,141,000Source | -193,340,000Source | -237,127,000Source | -306,557,000Source | -128,259,000Source |
| Income Tax Expense (Benefit)USD | — | — | 8,626,000Source | -31,000Source | 425,000Source | 948,000Source | 488,000Source | 496,000Source | 5,631,000Source | 2,429,000Source | 1,921,000Source | -1,470,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -80,529,000Source | -44,378,000Source | -37,719,000Source | -56,299,000Source | -53,535,000Source | -43,637,000Source | -198,971,000Source | — | — | — |
| Earnings Per Share, BasicUSD per share | — | — | -1.38Source | -0.91Source | -0.69Source | -1.16Source | -0.85Source | -0.82Source | -3.46Source | -4.92Source | -6.47Source | -2.71Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.38Source | -0.91Source | -0.69Source | -1.16Source | -0.85Source | -0.82Source | -3.46Source | -4.92Source | -6.47Source | -2.71Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 58,516,415Source | 48,718,533Source | 54,807,967Source | 48,622,440Source | 62,742,847Source | 53,110,580Source | 57,502,068Source | 48,649,129Source | 47,670,986Source | 46,735,045Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 58,516,415Source | 48,718,533Source | 54,807,967Source | 48,622,440Source | 62,742,847Source | 53,110,580Source | 57,502,068Source | 48,649,129Source | 47,670,986Source | 46,735,045Source |
| Interest Expense (non-operating)USD | — | — | 16,721,000Source | 16,611,000Source | 15,591,000Source | 16,157,000Source | 14,031,000Source | 15,109,000Source | 61,994,000Source | 63,741,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 54,202,000Source | 43,191,000Source | 49,539,000Source | 56,883,000Source | 49,463,000Source | 47,245,000Source | 207,815,000Source | 214,766,000Source | 303,083,000Source | 255,993,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | 7,521,000Source | 89,000Source | — | — | — | — | 4,043,000Source | 145,000Source | 110,000Source | 24,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 2,956,000Source | 4,527,000Source | 14,759,000Source | — | — | 8,537,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -428,000Source | 7,564,000Source | 18,638,000Source | -989,000Source | -2,294,000Source | 7,172,000Source | 26,131,000Source | -10,507,000Source | -1,691,000Source | 23,235,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -174,507,000Source | -215,251,000Source | -282,530,000Source | -96,872,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 41,557,000Source | 11,704,000Source |
| Investment Income, InterestUSD | — | — | 3,503,000Source | 4,866,000Source | 3,524,000Source | 5,805,000Source | 5,229,000Source | 4,127,000Source | 16,967,000Source | 21,415,000Source | 19,562,000Source | 609,000Source |
| Labor and Related ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 135,728,000Source | 119,903,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -44,378,000Source | — | -56,299,000Source | — | -43,637,000Source | -198,971,000Source | -239,556,000Source | -308,478,000Source | -126,789,000Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 289,455,000Source | 252,650,000Source |
| Other Cost and Expense, OperatingUSD | — | — | — | — | — | — | — | — | — | — | 11,236,000Source | 8,510,000Source |
| Other ExpensesUSD | — | — | 2,044,000Source | 1,915,000Source | 2,185,000Source | 236,000Source | 1,451,000Source | 1,959,000Source | 8,042,000Source | 4,573,000Source | 1,690,000Source | 820,000Source |
| Other IncomeUSD | — | — | 1,510,000Source | 2,591,000Source | 2,597,000Source | 1,983,000Source | — | 8,306,000Source | 14,410,000Source | 7,926,000Source | 6,059,000Source | 7,171,000Source |
| Other Operating IncomeUSD | — | — | 9,000Source | 16,000Source | 404,000Source | 148,000Source | 1,632,000Source | 8,306,000Source | 628,000Source | 101,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 34,366,000Source | 30,595,000Source | 35,383,000Source | 33,655,000Source | 29,176,000Source | 36,140,000Source | 140,673,000Source | 143,782,000Source | 214,864,000Source | 197,591,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | 2,549,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 3,701,000Source | 2,287,000Source | 5,262,000Source | 11,126,000Source | — | 1,567,000Source | 16,098,000Source | 27,119,000Source | 15,843,000Source | 106,483,000Source |
| Total Revenue | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
Filing attachments
tm2628930d1_ex99-1.htm · 8-K · 2026-11-04
Exhibit 99.1 uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update ~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study design; U.S. patient screening expected to begin by end of 2026 ~ ~ Cash, cash equivalents and investment securities of approximately $768.4 million as of September 30, 2026 expected to fund operat…
Read attachment ↗tm2628699d1_ex99-1.htm · 8-K · 2026-11-02
Exhibit 99.1 uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease ~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatment for Huntington’s disease ~ Lexington, MA and Amsterdam, the Netherlands, November 2, 2026 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transfor…
Read attachment ↗tm2626514d1_ex99-1.htm · 8-K · 2026-09-29
Exhibit 99.1 Ashley – Huntington’s Disease Community Advocate Phase I/II ifezuntirgene inilparvovec (AMT-130) Huntington’s Disease Program Update September 29, 2026 ──────────────────────────── LEADERSHIP IN GENE THERAPY SEPTEMBER 2026 | 2 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements…
Read attachment ↗tm2626514d1_ex99-2.htm · 8-K · 2026-09-29
Exhibit 99.2 uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression ~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease prog…
Read attachment ↗qure-20260902xex99d1.htm · 8-K · 2026-09-02
EX-99.1 2 qure-20260902xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease ~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene inilparvovec in the U.K. ~ ~ Both submissions are supported by the three-year data analysis from the Phase I/II study, in which ifezuntirgene inilparvovec demonstrated a slowing of disease progression ~ Lexingt…
Read attachment ↗qure-20260729xex99d1.htm · 8-K · 2026-07-29
EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early b…
Read attachment ↗